This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

reputable news agency


Fluticasone furoate does not cut time to COVID-19 symptom resolution: Study

Fluticasone furoate does not cut time to COVID-19 symptom resolution

For outpatients with mild-to-moderate COVID-19, inhaled fluticasone furoate does not shorten time to symptom resolution, according to a study published in the Sept. 21 issue of the New England Journal of Medicine.

David R. Boulware, M.D., M.P.H., from the University of Minnesota in Minneapolis, and colleagues examined the effectiveness of inhaled glucocorticoids in shortening the time to symptom resolution or prevention of hospitalization or death among outpatients with mild-to-moderate COVID-19. Nonhospitalized adults aged 30 years or older with at least two symptoms of acute infection that had been present for no more than seven days before enrollment were randomly assigned to inhaled (200 µg once daily for 14 days) or (656 and 621, respectively).

The researchers observed no evidence for fluticasone furoate resulting in a shorter time to recovery compared with placebo (hazard ratio, 1.01; 95% credible interval, 0.91 to 1.12; posterior probability of benefit, 0.56). Overall, 3.7 and 2.1% of patients in the fluticasone furoate and placebo groups, respectively, had urgent care or emergency department visits or were hospitalized (hazard ratio, 1.9; 95% credible interval, 0.8 to 3.5). In each group, three participants were hospitalized; there were no deaths reported. In both groups, adverse events were uncommon.

"Our trial did not identify a clinically relevant effect associated with inhaled fluticasone furoate at a daily dose of 200 μg for 14 days as outpatient treatment for COVID-19 when delivered directly to the participant along with written instructions for use of the inhaler," the authors write.

More information: David R. Boulware et al, Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19, New England Journal of Medicine (2023). DOI: 10.1056/NEJMoa2209421

Journal information: New England Journal of Medicine

2023 HealthDay. All rights reserved.

Citation: Fluticasone furoate does not cut time to COVID-19 symptom resolution: Study (2023, September 21) retrieved 6 December 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Study finds no benefit to taking fluticasone furoate for COVID-19 symptoms


Feedback to editors